ProKidney Corp.
NASDAQ:PROKBiotechnology
+$0.02 today
- Market cap
- $349.70M
- Beta
- 1.70
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$0.53
Volume 1.80M
Average 0.96M
PROK Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
ProKidney Corp.NASDAQ: PROK
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables dips below year-ago levels
Q1 FY2026 accounts receivables of $95K fell 86.3% year over year, behind the +373.7% change in trailing-twelve-month accounts receivables. Sequentially, it fell 13.6% from the prior quarter.
Context
- Accounts receivables amounted to 147.8% of revenue in FY2025, down 1262.7 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -86.3% toward the trailing-twelve-month pace of +373.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 1.32M USD
- Year-over-year change
- +223.1%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.32M | +223.1% |
| FY2024 | 2024-12-31 | (1.07M) | +22.0% |
| FY2023 | 2023-12-31 | (1.38M) | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Accounts Receivables vs competitors
How PROK compares with its peers on the latest reported figures
- PROK's LTM Mar 2026 accounts receivables of $720K is the 4th largest of the 7 companies compared; the peer median is $6.94M.
- Its year-over-year change of +373.7% is the highest of 4, against a peer median of -76.0%.
- Accounts receivables amounts to 81.0% of revenue for PROK, versus a peer median of 8.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $36.37M | +98.7% | +25.1% | 8.5% | |
| LTM Mar 2026 | $20M | — | — | 100.0% | |
| LTM Sep 2026 | $13.84M | -76.0% | +168.7% | 2.1% | |
| LTM Mar 2026 | $720K | +373.7% | — | 81.0% | |
| LTM Mar 2026 | $49.73K | -134.1% | — | — | |
| LTM Dec 2024 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding PROK) | $6.94M | -76.0% | +96.9% | 8.5% | |
Competitors are the stored peer set for PROK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (55.15M) | (148.14M) | (135.45M) | (163.34M) | (151.61M) |
| Depreciation & Amortization | 1.98M | 3.04M | 3.85M | 5.43M | 6.58M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 699K | 74.47M | 30.85M | 29.37M | 25.34M |
| Change in Working Capital | 2.16M | (6.46M) | 16.67M | 3.96M | 1.28M |
| Accounts Receivables | 0 | 0 | (1.38M) | (1.07M) | 1.32M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 5K | 494K | 11.64M | 11.59M | (5.92M) |
| Other Working Capital | 2.16M | (6.95M) | 6.41M | (6.56M) | 5.88M |
| Other Non-Cash Items | 0 | 0 | (6M) | (1.78M) | (1.7M) |
| Operating Cash Flow | (50.3M) | (77.09M) | (90.07M) | (126.35M) | (120.12M) |
| Capital Expenditures | (5.19M) | (1.85M) | (34.2M) | (29.51M) | (15.2M) |
| Acquisitions (Net) | 1K | 108K | 0 | 0 | 18.22M |
| Purchases of Investments | 0 | 0 | (471.6M) | (324.02M) | (217.08M) |
| Sales of Investments | 0 | 0 | 175.82M | 373.95M | 318.02M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (5.19M) | (1.74M) | (329.98M) | 20.41M | 103.97M |
| Debt Repayment | (30K) | (32K) | (52K) | (54K) | (26K) |
| Common Stock Issued | 71.5M | 6.05M | 0 | 144.32M | 25.6M |
| Common Stock Repurchased | 0 | 0 | (9.5M) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 542.5M | 0 | 140K | 0 |
| Financing Cash Flow | 71.47M | 548.52M | (9.55M) | 144.41M | 25.57M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 15.98M | 469.69M | (429.6M) | 38.47M | 9.42M |
| Free Cash Flow | (55.49M) | (78.94M) | (124.27M) | (155.86M) | (135.31M) |
ProKidney Corp.
NASDAQ:PROK
Intrinsic Alpha fair value
Locked
Current Price
$1.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.